



Press Release | Munich, 12th January, 2010

FGK Clinical Research established office in Prague

and become major shareholder in the former Avemedica s.r.o.

FGK Clinical Research GmbH today announced that it has increased its investment and become major shareholder in the Czech contract research organization Avemedica s.r.o. With immediate effect the Czech company will operate as FGK Clinical Research s.r.o. and will be an integral part of the FGK Clinical Research group.

FGK Clinical Research s.r.o. is specialized in local services in terms of regulatory affairs, project management and monitoring in Czech Republic and Slovakia. With its highly skilled, motivated and experienced team, FGK Clinical Research s.r.o. operates out of Prague.

In order to guarantee our customers the highest possible level of quality and service we constantly strive to extend our network of offices in Europe. The takeover is a further step in our strategy to continue to strengthen our European network.

FGK Clinical Research GmbH is a full service contract research organization offering the complete range of clinical development and consulting services to pharmaceutical, biotechnology and medical device companies. With more than 60 highly skilled and experienced people, FGK operates from Munich on local and global projects, covering clinical studies, phases I to IV. FGK has extensive experience in all major therapeutic areas allowing it to effectively design, manage and analyse development programs and clinical trials.

For further information please contact:

Ina Ott

Director Business Development

T | +49 89 893119-44

E | ina.ott@fgk-cro.com



fgk-cro.com

FGK Clinical Research GmbH

Heimeranstrasse 35

80339 Munich | Germany